Richland, WA (May 11, 2015) – – IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that a number of industry leaders discussed the successes achieved by their patients in a variety of body sites being treated with IsoRay’s Cesium-131 internal radiation (brachytherapy) cancer seeds at the “Advances in Brachytherapy” symposium, held at Weill Cornell on Friday and Saturday.
IsoRay Chairman and CEO Dwight Babcock commented, “We are so very pleased to have studies presented reporting successes in peer to peer presentations. Data from ongoing studies continues to be gathered and when it matures the expectation is that it will be peer reviewed and published. We are now hearing from more institutions based on our new recently released peer reviewed publications. Medical professionals rely on these publications to further their practice and learn about new leading edge products.”
NOTES FROM THE FIELD AT THE SYMPOSIUM
1.) LDR Brachytherapy: MD Anderson Experience – Steve Frank, M.D.
Dr. Frank discussed the ongoing prostate cancer trial at MD Anderson Cancer Center in Houston, including the use of Cesium-131 as treatment. He also discussed the emerging use of magnetic resonance (MR) imaging in determining radiation doses delivered following prostate brachytherapy. Cesium-131 was the first isotope chosen to be used in conjunction with the MRI spacer.
2.) Role of Brachytherapy in Recurrent H&N Cancers – Bhupesh Parashar, M.D.
Dr. Parashar discussed the option of Cesium-131 brachytherapy as part of the management of recurrent head and neck cancers. Details on this study were recently presented at the 97th Annual Meeting of the American Radium Society.
3.) Resection with intraoperative Cs-131 Brachytherapy in Newly Diagnosed Brain Metastases and Recurrent GBM: Techniques and Outcomes – Theodore Schwartz, M.D. and A. Gabriella Wernicke, M.D.
Drs. Schwartz and Wernicke described their study, published recently in the Journal of Neurosurgery, where very high rates of control have been seen in the treatment of metastatic brain cancer. In particular they noted the benefit of cesium-131 treatment in tandem with surgery over waiting weeks or months to perform other types of radiation treatment. Their group continues to add patients to their existing study and they are planning a trial to compare cesium-131 treatment to other radiation treatments in the treatment of brain metastases.
4.) Impact of Brachytherapy on Local Recurrence Rates after Sublobar Resection in Early Stage Non-Small Cell Lung Cancer – Bhupesh Parashar, M.D.
Dr. Parashar discussed the role of cesium-131 brachytherapy in addition to lung sparing wedge resection surgery for patients with operable lung cancers. Although there is some discussion ongoing regarding the use of brachytherapy in these cases, Dr. Parashar stated that he continues to see the value of cesium-131 brachytherapy for appropriately selected patients.
IsoRay Chairman and CEO Dwight Babcock noted, “Cesium-131 continues to impress medical professionals as reported successes are showing positive results in treating some of the toughest cancer cases. Many of our cases are brought by physicians seeking solutions where first line treatments have failed. Following Cesium-131 treatment, patients are having better outcomes with improved quality of life. Therapy with Cs-131 is successfully treating patients who failed conventional therapies and we believe that it could help many other patients. We are extremely excited to see that Cesium-131 isotope seeds continue to perform so well against aggressive cancers throughout the body. We remain committed to helping patients afflicted with these horrible cancers and enhancing their quality of life.”
IsoRay’s various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite®radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay’s cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay’s future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of our products will increase or continue, whether we will continue to receive support from industry leaders, whether awareness and adoption of our products in the medical community will continue or increase, whether ultimate study results will be favorable or will ultimately be peer reviewed and published, whether future studies of treatment of various cancers using our products will have favorable results, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay’s reports filed with the SEC.